Skip to main content

Table 1 Baseline information of two groups. Values are given as the mean (SD) or number (proportion)

From: Potential influence of anaesthesia techniques on the recurrence and progression after resection of non-muscle-invasive bladder cancer: a propensity score-matched analysis

Covariate Before propensity match score After propensity match score
  Group G
n = 662
Group E
n = 264
P valve Group G
n = 264
P valve
Age 58.32 ± 12.703 56.62 ± 13.809 0.073 58.54 ± 11.968 0.088
Height 165.45 ± 6.903 165.945 ± 7.090 0.329 165.417 ± 7.102 0.393
Weight 63.66 ± 10.144 63.364 ± 10.608 0.693 63.520 ± 10.706 0.866
Gender    0.076   0.170
 male 571 (83.6%) 239 (90.5%)   229 (86.7%)  
 female 91 (13.7%) 25 (9.5%)   35 (13.3%)  
Hypertension    0.095   0.662
 yes 159 (24.0%) 50 (18.9%)   54 (20.5%)  
 no 503 (76.0%) 214 (81.1%)   210 (79.5%)  
Diabetes mellitus    0.495   0.579
 yes 43 (6.5%) 14 (5.3%)   17 (6.4%)  
 no 619 (93.5%) 250 (94.7%)   247 (93.6%)  
TNM stage    0.697   0.609
 TaN0M0 507 (76.6%) 199 (74.5%)   204 (77.3%)  
 T1N0M0 155 (23.4%) 65 (24.6%)   60 (22.7%)  
Grade    0.060   0.226
 Low malignant potential 155 (23.4%) 74 (28.0%)   63 (23.9%)  
 Low-grade papillary urothelial carcinoma 291 (44.0%) 124 (47.0%)   118 (44.7%)  
 High-grade papillary urothelial carcinoma 216 (32.6%) 66 (25.0%)   83 (31.4%)  
Tumour size    0.169   0.786
 < 3 cm 450 (68.0%) 167 (63.3%)   170 (64.4%)  
 ≥ 3 cm 212 (32.0%) 97 (36.7%)   74 (35.6%)  
Number of tumour    0.150   0.207
 Solitary 432 (65.3%) 159 (60.2%)   173 (65,5%)  
 Multiple 230 (34.7%) 105 (39.8%)   91 (34.5%)  
Risk group    0.163   0.500
 High-risk tumour 267 (40.3%) 92 (34.8%)   105 (39.8%)  
 Intermediate-risk tumour 187 (28.2%) 90 (34.1%)   82 (31.1%)  
 Low-risk tumour 208 (31.4%) 82 (31.1%)   77 (29.2%)  
Intravesical chemotherapy    0.976   0.595
 yes 264 (39.9%) 105 (39.8%)   111 (42.0%)  
 no 398 (60.1%) 159 (60.2%)   153 (58.0%)